Invox pharma's f-star announces licence agreement with takeda for second novel next-generation immuno-oncology bispecific antibody

London--(business wire)--f-star, an invox company, has entered into a second licence agreement with takeda for a novel next-generation immuno-oncology bispecific antibody
TAK Ratings Summary
TAK Quant Ranking